Clinical Trials Logo

Mild Hyperphenylalaninemia clinical trials

View clinical trials related to Mild Hyperphenylalaninemia.

Filter by:
  • None
  • Page 1

NCT ID: NCT01924026 Completed - Phenylketonuria Clinical Trials

Neurocognitive Outcomes in Mild Hyperphenylalaninemia (MHP)MHP Study

Start date: September 2013
Phase: N/A
Study type: Observational

Phenylketonuria (PKU) is a genetic disorder known to cause severe reduction in intelligence and deficits in cognitive function; it is associated with an elevated level of Phenylalanine (Phe) in blood. Newborn screening and early treatment with restricted protein diet supplemented by a formula of amino-acids will preserve intelligence. In those with the severe form treated from birth, some deficits that affect higher functions of the brain are seen. Given this, there is disagreement about how milder forms of this disease should be managed and what level of Phe is safe to be left untreated. We seek to assess whether higher Phe levels, between 360 and 600µmol/L, are safe with respect to preservation of intelligence and higher cognitive functions.